



ACURATE *neo*[™]

Aortic Valve System

Next-Day Discharge with ACURATE *neo* vs. SAPIEN 3

Safety of next-day discharge (NDD) after transfemoral transcatheter aortic valve replacement with a self-expandable vs. balloon-expandable valve prosthesis: ACURATE *neo* vs. SAPIEN 3


Moriyama N, Vento A, Laine M. *Circ Cardiovasc Interv.* 2019;12:e007756. DOI: 10.1161.

Study Design

A total of 249 consecutive patients who underwent elective transfemoral-TAVI (146 ACURATE *neo*, 103 SAPIEN 3) using minimalist approach (local anesthesia, transthoracic echocardiogram, transfemoral access, and complete percutaneous vascular closing) between January 2017 and July 2018 at Helsinki University Central Hospital were reviewed. The objectives of the study were (1) to assess the success rate of NDD with ACURATE *neo* and (2) to evaluate the safety of NDD after ACURATE *neo* implantation compared with SAPIEN 3 after 90 days and after 1 year.



Clinical Highlights

Rates of device success and NDD with ACURATE *neo* are comparable to SAPIEN 3. Additionally, ACURATE *neo* patients show similar in-hospital complication rates with no significant differences.



NDD with ACURATE *neo* is safe

ACURATE *neo* shows low 90-day complication rates in patients discharged next day after TAVR with no significant differences vs. SAPIEN 3. Moreover, the 1-year safety of NDD after ACURATE *neo* implantation is equivalent to that after SAPIEN 3 implantation.

90-Day Outcomes After NDD

All-Cause Mortality After NDD in Patients Receiving ACURATE *neo* or SAPIEN 3


ACURATE <i>neo</i>	87	84	80	69	65	60	55	45	39	32
SAPIEN 3	57	54	51	46	45	42	40	34	30	23